Resolution is developing its liquid biopsy assay as a companion diagnostic for niraparib in metastatic castration-resistant prostate cancer.
Qiagen's test is intended to identify advanced bladder cancer patients with alterations in FGFR3 or FGFR2 genes and who are likely to respond to erdafitinib.
VALUE-Dx involves six IVD companies and is being heralded by participants as an opportunity for competitors to work together to improve test adoption.
The companies will evaluate the performance of Proteomics International's PromarkerD test for predicting decline in kidney function and drug response.
Saladax will have the patent rights to Janssen Pharmaceutica's tests that determine drug levels in patients undergoing treatment with antipsychotic drugs.
The company is planning to submit the drug and a companion diagnostic that can identify patients with FGFR alterations with the FDA in the second half of 2018.
GenomeDx will test its Decipher GRID database of cancer genomic profiles with samples from Janssen-run prostate cancer clinical trials.
The partners will develop an amyloid β 42/40 ratio assay to identify patients who may benefit from treatment with Janssen's drug called atabecestat.
Sebia and Janssen Biotech collaborated on the development of the test, which is for assessing patients treated with Darzalex.
Genomic Health will test samples from Janssen prostate cancer drug studies to examine whether its test can predict patient outcomes.